David Webb


Dr. Webb is currently CEO of Synbal(www.synbal.com), Chairman of the Board at Agragene (www.agragene/com)and Adjunct Professor at The Scripps Research Institute (TSRI).  He was Chairman of the Board of Sorrento Therapeutics from 2012-2014and is also former chairman of the Board of BIOCOM (2012), a former member of the Executive Committee of the Board of CONNECT, a member of the Board of Directors of the La Jolla Institute of Allergy and Immunology, and a member of the dean’s Advisory Council of the College of Science and Mathematics at Cal State University, San Marcos.  He also serves as a consultant and advisor to several biotechnology and pharmaceutical companies.

Dr. Webb joined Celgene-San Diego in September2003 as Vice President, Research. During this time, the Research Division placed six drugs into clinical development; four of which are still in clinical studies (Phases I and II) in the areas of cancer and inflammation/autoimmunity (one with Array Biopharma). He was the first Project Leader for the development of Otezla (Apremilast) leading it through its IND and Phase I trials; now approved for psoriasis and other autoimmune diseases.  Between 1995 and 2003, he held a series of senior management positions in several biotechnology companies where he developed and led drug discovery programs focused on inflammation, asthma, cancer, and diabetes. These included Syrrx (Vice President of Drug Discovery, 2001-2003)where he led a team that discovered and developed a log liptin for type II diabetes; OSI Pharmaceuticals(Corporate Vice President, Drug Discovery 1999-2001)where he was associated with the development of Tarceva; and Cadus PharmaceuticalCorporation (Vice President of Research and Chief Scientific Officer, 1995-99)and also Adjunct Professor of Microbiology and Immunology at New York Medical College. From 1987 to 1995, Dr. Webb was at Syntex, Inc., (Distinguished Scientist and Director, Institute of Immunology and Biological Sciences)and was responsible for all of the inflammation and immunology research programs world-wide. He was part of the development team for CellCept.He was also a consulting professor of Cancer Biology at Stanford University. From 1973-1987 he was an Associate Member of the Department of Cell Biology, Roche Institute of Molecular Biology and Adjunct Associate Professor at Columbia University, College of Physicians and Surgeons. From 1971-73 he was a Dernham Junior Fellow of the American Cancer Society, California Division at UCSF.  He received his Ph.D. from Rutgers University in 1971. He has published over 200 papers and abstracts and has been a member of numerous editorial boards and study sections in Immunology.